Benech J M, Kulling G
Médecin Conseil national, Paris, France.
Bull Cancer. 1995 Jul;82 Suppl 3:230s-231s.
Faced with scientific progress, social security must be concerned by ethics, especially by protection of personal integrity. Financial necessities lead to take into account the efficiency of public health interventions. But in front of potentially toxic drug, are we allowed to compare possible advantages with potentially serious risks for healthy women? For these reasons, social security takes a stand in favour of carefully controlled trials, focused on restricted target populations which are estimated at high risk of cancer. Research of side effects should be included in the follow of the patients and special caution should be taken to avoid premature spreading of this behaviour. About a financial contribution of social security, the National fund for health prevention, education and information (FNPEIS) could perhaps not support such a project, regarding to his experimental nature. CNAMTS-INSERM research contracts could be an alternative.
面对科学进步，社会保障必须受到伦理的关注，尤其是对个人完整性的保护。经济需求导致必须考虑公共卫生干预措施的效率。但是面对潜在有毒的药物，我们是否可以将对健康女性可能的益处与潜在的严重风险进行比较呢？出于这些原因，社会保障支持进行严格控制的试验，试验对象集中在估计患癌风险较高的特定目标人群。副作用研究应纳入患者随访过程，并且应格外谨慎，避免这种行为过早扩散。关于社会保障的资金贡献，鉴于该项目的实验性质，国家健康预防、教育和信息基金（FNPEIS）可能无法支持这样一个项目。国家医疗保险基金（CNAMTS）-国家健康与医学研究院（INSERM）的研究合同可能是一种选择。
